Back

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Real-world evidence on the cardiovascular effects of therapies for diabetes Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Spyridon Maragkoudakis

General Hospital St. George, Chania (Greece)

8 More presentations in this session

Presentation thumbnail
Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis
Mr B. Tan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank
Doctor T. Guo (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries
Doctor P. Yazdanfard (Hilleroed, DK)
Abstract Slides Video
Presentation thumbnail
Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.
Doctor M. Feola (Mondovi, IT)
Abstract Slides Video
Presentation thumbnail
Identification and optimisation of a risk stratified cohort of patients with type 2 diabetes through the delivery of a enhanced pharmacist-led service
Mr S. Mcbrien (Belfast, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Real-world evidence on the cardiovascular effects of therapies for diabetes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity
thumbnail
Congress Presentation
SGLT2 inhibitors and cardiotoxicity in diabetic patients receiving anthracycline therapy: a retrospective study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources